Needham & Company downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Buy to Hold.Analsyt Alan Carr commented, "Lexicon reported $5.4M U.S. Xermelo ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE